Answers are grounded in this paper and cite their sources.
A key concern with the use of antibody-drug conjugates (ADCs) is the presence of tumor-associated antigens (TAAs) on non-diseased tissue. While ADCs leverage the upregulation of TAAs on diseased cells to create the therapeutic window, basal expression on healthy cells underlies on-target, off-tumor side effects. Engineering ADCs to further increase specificity is thus a major consideration in next-generation drug development. A promising strategy is the use of multivalent antibodies with low monovalent affinity to specifically target high-expressing cells that can be avidly bound. This, however, does not rule out multivalent binding on cells with low expression but high-density antigen patches, ultimately limiting selectivity. Addressing this, we introduce an alternative selectivity mechanism based on surface antigen depletion. Specifically, we generated a tetravalent, rapidly internalizing ADC specific to the T-cell acute lymphoblastic leukemia (T-ALL) target CD7. We show that this format can bind CD7high and CD7low cells with similar strength due to the avidity effect, while also inducing total antigen depletion due to fast internalization kinetics. Thus, total ADC uptake is limited by available surface antigen levels, resulting in extreme selectivity toward CD7high cells. CD7low cells are conversely spared, due to complete depletion of surface antigen before a lethal ADC dose can be internalized. Ultimately, this provides a method to potentially reduce on-target, off-tumor side effects, consequently improving ADC specificity even when low-expressing cells are susceptible to avid binding.
No takes yet. Share an insight, caveat, or question.
Abdellatif et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: